Hope to resolve Srikakulam with US FDA soon, says DRL

From the pharmaceutical space, Dr Reddys Laboratories (DRL) reported a mixed set of earnings this quarter. In an interview to CNBC-TV18, Saumen Chakraborty, CFO of DRL discussed the company's Q3 performance.

Chakraborty said that Renvela, definitely has helped us during the quarter. And, despite being second to launch, we have been able to tap specific channels. The contracted market share has been there but it has resulted in recent months. But, of course now there are more players. There are 5 players already in the market. So going forward, it might not be able to give similar kind of opportunity.

Talking about Srikakulam plant, he said we responded to the queries that we received from the US Food and Drug Administration (US FDA), and we hope to resolve that soon with the US FDA.

Watch accompanying video for more details.